Objectives: The study's goal is to find out if there is a link between the results of the 6-minute walk test (6MWT) done before surgery and the chance of getting pneumonia after surgery in people with stage I lung cancer who are having a video-assisted thoracoscopic lobectomy.
Methods: We conducted a retrospective analysis on data from 194 patients with lung cancer who underwent VATS lung resection between January 2020 and August 2023. We assessed the preoperative 6MWT findings and the likelihood of developing postoperative pneumonia using a logistic regression model.
Results: Pneumonia developed in 23 patients (11.9%) in the early postoperative period. Risk factors led to the exclusion of 12 patients leaving 11 patients in the study. Eight of the patients were male three were female and the average age was 51±6 years. Postoperative pneumonia was observed to be statistically significantly more likely to occur in those whose 6MWT outcomes were less than 300 meters (p <0.05).
Conclusion: We found that patients who underwent VATS lung resection due to pulmonary malignancy and had a preoperative 6MWT result below 300 meters were at risk for developing postoperative pneumonia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729831 | PMC |
| http://dx.doi.org/10.14744/SEMB.2024.34341 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fibrosis in PCLS: comparing TGF-β and fibrotic cocktail.
Respir Res
January 2025
Department for Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Introduction: Fibrotic cocktail (FC) is a combination of pro-fibrotic and pro-inflammatory mediators that induces early fibrotic changes in organotypic lung models. We hypothesised that transforming growth factor beta 1 (TGF-β1) alone induces a pro-fibrotic effect similar to FC. Our aim was to compare the pro-fibrotic effects of TGF-β1 with FC in human precision-cut lung slices (PCLS).
View Article and Find Full Text PDFInvestigating orbital foreign device-associated malignancies: a scoping review.
BMC Cancer
January 2025
Department of Plastic Surgery, University of California, Irvine, CA, USA.
Background: While prosthesis-associated malignancies have been acknowledged, awareness among surgeons and patients in the ophthalmologic field remains limited, despite the frequent occurrence of prosthesis-related surgeries. We aim to address this gap through a scoping review of malignancies following ophthalmologic surgeries involving various foreign device/prosthesis/implants.
Methods: Following PRISMA guidelines, we conducted a review using PubMed and Embase for studies on cancer and ophthalmic prostheses/implants.
Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer.
Pharmacoecon Open
January 2025
Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Objectives: Immune checkpoint inhibitor (ICI)-containing treatment is currently prescribed as first-line treatment for all patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. However, only 30-45% of patients show no progression within 12 months after treatment start. Various biomarkers are being studied to save costly and potentially harmful treatment in non-responders.
View Article and Find Full Text PDFA human metabolic map of pharmacological perturbations reveals drug modes of action.
Nat Biotechnol
January 2025
Department of Biomedicine, University of Basel, Basel, Switzerland.
Understanding a small molecule's mode of action (MoA) is essential to guide the selection, optimization and clinical development of lead compounds. In this study, we used high-throughput non-targeted metabolomics to profile changes in 2,269 putative metabolites induced by 1,520 drugs in A549 lung cancer cells. Although only 26% of the drugs inhibited cell growth, 86% caused intracellular metabolic changes, which were largely conserved in two additional cancer cell lines.
View Article and Find Full Text PDFDiagnostic utility of chest wall vessel involvement sign on ultra-high-resolution CT for primary lung cancer infiltrating the chest wall.
Eur Radiol
January 2025
Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.
Objectives: Chest wall infiltration in primary lung cancer affects the surgical and therapeutic strategies. This study evaluates the efficacy of the chest wall vessel involvement in subpleural lung cancer (CWVI) on ultra-high-resolution CT (UHR-CT) for detecting chest wall invasion.
Materials And Methods: A retrospective analysis of lung cancer cases with confirmed pleural and chest wall invasion was conducted from November 2019 to April 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!